KabaFusion signs deals with UCB
By HME News Staff
Updated 10:36 AM CDT, Thu August 3, 2023
CERRITOS, Calif. – KabaFusion has been selected by UCB as a limited distribution partner to provide RYSTIGGO (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis in certain adult patients. “KabaFusion is proud to be a leader in home infusion and providing access to patients with new drugs that will improve their quality of life,” said Dr. Sohail Masood, founder and CEO. “We have a well-established history of successfully managing patients with myasthenia gravis and neuromuscular conditions and we are proud to have been selected by UCB as a limited distribution partner to provide RYSTIGGO to patients and providers.” People living with generalized myasthenia gravis can experience a variety of symptoms, including severe muscular weakness of the muscles of respiration, double vision, drooping eyelids, and difficulty swallowing, chewing and talking.
Comments